News | Radiopharmaceuticals and Tracers | April 28, 2017

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields

New method utilizes transition metal rhenium to eliminate the need for dry conditions and purification steps

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields

April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new method for producing positron emission tomography (PET) radiotracers. The discovery utilizes the transition metal rhenium to promote fluorine-18 radiolabelling under aqueous, low temperature conditions. The method circumvents the need for dry conditions, and purification steps, which saves time and gives PET radiotracers in very high yields. 

Fluorine-18, the most commonly used radioisotope in PET imaging, must be attached to vectors in order to diagnose disease. The best example is where fluorine-18 is attached to glucose in order to make [18F]FDG for cancer imaging.

This new method has the potential to improve production of PET radiotracers like FDG, but also facilitate development of new radiotracers by allowing previously challenging vectors to be radiolabelled in high yields under mild conditions.  

Because a radiotracer decays, radio-synthesis needs to be performed quickly, efficiently and in high yield, so there is enough radiotracer to scan all patients at a PET medical center.  

“Improving methods for incorporation of fluorine-18 has been a longstanding challenge for the radiotracer community. This research is the first example of a rhenium promoted radio-fluorination, an unprecedented, exciting discovery in the radiochemistry field,” said senior author Benjamin Fraser, M.D., Radiotracer Method and Organic Chemistry Task leader at ANSTO.

Fraser explained that a rhenium complex was selected because of its potential for development as a dual modality PET/optical imaging agent. PET allows diagnosis of tumor location and then optical luminescence guides surgical removal of the tumor.

“The choice of rhenium proved fortuitous for the incorporation of F-18 and was good example of ‘chance favoring the prepared mind’ as the result was not predicted but very significant,” said Fraser.

“It’s also important that the reaction can be done in water, as this simplifies subsequent formulation of the radiotracer in saline for injection into a patient in a clinical setting,” he added.

The study involved the use of microfluidic technologies that had several advantages for the investigation. Giancarlo Pascali, M.D., co-senior investigator on the project who is based at the Camperdown cyclotron facility, supervised the radiochemistry work under microfluidic radiolabelling conditions.

“Microfluidic technologies allowed us to optimize all the reaction parameters very quickly, such as temperature, time, solvent and additives. We can optimize a given radiolabelling reaction in only three days, which under normal conditions would take one month to complete.

Another benefit of microfluidics is that we work with only very small amounts of radioactivity,” said Fraser.

Fraser points out that at this stage the radiotracer has not been tested for use with PET. “The next step is working on conjugating the tracer to new biological vectors, but also applying the new rhenium method to established radiotracers. We can then also investigate its potential use as a dual modality probe,” he said.

A large team of researchers from the Human Health and the Radioisotopes and Radiotracers platform at ANSTO, Curtin University, The University of Sydney, Monash University and Western Sydney University contributed to the study, which has just been published in Chemistry – A European Journal.

Ph.D. student Mitchell Klenner, who received an Australian Institute of Nuclear Science and Engineering (AINSE) post graduate scholarship, has been invited to present the work at The International Symposium on Radiopharmaceutical Sciences in May 2017.

Klenner will receive the prestigious Wiley Award at the conference in recognition of the impact of the work. Recently he also presented the work at Innovations and Radiation Applications 2017 in Wollongong and received the industry-sponsored award for best student presentation.

Fraser said, “It is fantastic to see Mitchell get due recognition for his diligent, hard work. His passion and enthusiasm for research at ANSTO is inspiring.”

For more information: www.onlinelibrary.wiley.com

Related Content

Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep

Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep (cool colors in the left columns), are reactivated when regaining a con-nected state upon emergence from anesthesia (warm colors in the right columns). Graphic courtesy of University of Turku

News | PET Imaging | December 30, 2020
December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging | December 22, 2020
December 22, 2020 — Researchers in the DO...
SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

SHINE executives and project leaders were joined by a City of Janesville official for the groundbreaking ceremony for the new corporate headquarters and therapeutics production facility on the SHINE campus in Janesville, Wis. (Photo: Business Wire)

News | Nuclear Imaging | December 18, 2020
December 18, 2020 — SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.

News | PET Imaging | December 14, 2020
December 14, 2020 — Positron emission tomography (PET) imaging with...

JNM celebrates 60 years of nuclear medicine research. Image courtesy of Society of Nuclear Medicine and Molecular Imaging.

News | Nuclear Imaging | December 14, 2020
December 14, 2020 — The Journal of Nuclear Medicine
Videos | PET-CT | December 04, 2020
This is an example of Canon's...
Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Feature | Nuclear Imaging | November 12, 2020 | By Willow Ascenzo
Medical imaging procedures such as single-photon emission computed tomography (...